Cartesian Therapeutics
RNAC
83 hedge funds and large institutions have $63.3M invested in Cartesian Therapeutics in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 32 reducing their positions, and 17 closing their positions.
0.18% less ownership
Funds ownership: 1.39% → 1.21% (-0.18%)
14% less funds holding
Funds holding: 96 → 83 (-13)
40% less capital invested
Capital invested by funds: $105M → $63.3M (-$42.2M)
47% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 32
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
63% less call options, than puts
Call options by funds: $18K | Put options by funds: $48K
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
+$3.15M |
| 2 |
DFG
Delphi Financial Group
Wilmington,
Delaware
|
+$937K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$473K |
| 4 |
Renaissance Technologies
New York
|
+$453K |
| 5 |
Citigroup
New York
|
+$411K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.53M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.17M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$944K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$914K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$903K |
RNAC Hedge Fund Activity: Q4 2022 in Review
83 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q4 2022, worth a combined $63.3M — down 40% from $105M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RNAC and 7 opened new positions — a net loss of 10 holders — while 32 trimmed existing stakes and 17 added.
The largest buyer was Ally Bridge Group, adding an estimated $3.15M. The largest seller was Millennium Management, cutting an estimated $4.53M.
- 83 institutional investors held Cartesian Therapeutics (RNAC) as of Q4 2022, down from 96 in Q3 2022.
- Funds reported $63.3M of Cartesian Therapeutics stock for Q4 2022, down 40% quarter-over-quarter.
- 7 funds opened new Cartesian Therapeutics positions in Q4 2022 and 17 closed out, a net change of -10 holders.
- The largest Cartesian Therapeutics buyer in Q4 2022 was Ally Bridge Group, an estimated $3.15M added.
- The largest Cartesian Therapeutics seller in Q4 2022 was Millennium Management, an estimated $4.53M sold.
Based on aggregated 13F filings for Q4 2022.